A Rebate Is Not a Recovery

Three of the largest device makers in the world reported second-quarter results in the last 48 hours, and all three booked money back from the U.S. government.

GE HealthCare recognized $129 million in International Emergency Economic Powers Act tariff refunds, lifting net income to $561 million from $486 million a year earlier. Philips booked €186 million, roughly 4.2 percentage points of its 16.4% adjusted EBITA margin. Boston Scientific recognized about $80 million in cost of products sold, which CFO John Monson told analysts represents substantially all of what the company expects to receive.

The money traces back to February 20, when the Supreme Court held 6–3 that IEEPA does not authorize the president to impose tariffs. The Court of International Trade subsequently ordered Customs and Border Protection to refund approximately $165 billion in duties collected across more than 53 million entries, and directed CBP to build an automated system to process them. Treasury Secretary Scott Bessent called the prospect “the ultimate corporate welfare” and predicted years of litigation. The checks cleared in about five months.

What matters for operators is not that the money arrived. It is what each company did with it in the disclosure.

GE HealthCare drew the sharpest line. Of the $129 million, the company excluded $106 million — the portion relating to 2025 duties — from adjusted figures entirely, keeping only $23 million, about four cents a share, in adjusted results. Then it reaffirmed full-year guidance without change. The underlying quarter carried its own weight: organic orders up 11.1%, backlog at a record $23.9 billion, book-to-bill of 1.15. Shares rose roughly 12% premarket.

Philips took the opposite approach and raised guidance on the strength of the refund, lifting its full-year adjusted EBITA margin target to 13.5%–14.0% from 12.5%–13.0% and free cash flow to €1.5–1.7 billion. The company acknowledged that without the one-time benefit, underlying profitability would have declined slightly on cost inflation. Investors noticed. The stock fell 9% Tuesday to its lowest level in a year, pressured further by new Chinese rules routing public hospital device purchases through a centralized state program.

Boston Scientific presented the cleanest illustration of the gap between the two numbers. Organic revenue grew 7%, at the high end of guidance. Adjusted EPS of $0.86 beat the range. And the company still cut its full-year organic growth outlook to 5%–6%, citing a slowdown in Watchman and competitive pressure in U.S. electrophysiology, while announcing a restructuring targeting roughly $500 million in run-rate savings by the end of 2029. The refund landed in the same quarter as a decision to take out half a billion dollars of cost.

The through-line: a tariff refund is a balance-sheet event that arrives dressed as an operating one. It flows through cost of goods or income from operations, it expands margin, and it does so with no relationship whatsoever to whether the underlying business improved. Every finance team in the industry now has one quarter in which the reported margin and the earned margin diverge, and a decision to make about how visible to render the difference.

The second point is more durable. The refunds close out a tariff regime that no longer exists — but the tariffs do. Within a day of the February ruling, the administration moved to replace the invalidated levies with a 10% across-the-board tariff under Section 122 of the Trade Act of 1974, and new duties covering 60 trading partners took effect this month. Philips said plainly that elevated tariff costs continue to pressure operations. GE HealthCare cited geopolitical instability weighing on costs, supply chains, and logistics.

So the industry got its money back for duties paid under a statute the Court rejected, and is now paying comparable duties under statutes it hasn’t. The refund is not relief. It is a reconciliation of one legal theory, arriving in the middle of a cost structure that hasn’t changed.

For anyone building a 2027 plan on the back of this quarter’s margin, the useful question is which number the board is going to remember — the one that includes the refund, or the one that shows what the business actually did.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

J&J’s Ottava cleared the FDA on July 22. That same day, Vicarious Surgical’s shareholders voted to liquidate a company that had raised more than $425 million. Read those two headlines together and you have the industry’s operating thesis for 2026: the barrier to entry in high-capital medtech categories is no longer the technology, it’s the balance sheet and the commercial infrastructure behind it. The same logic showed up everywhere last week — Tempus buying its way into tumor-informed MRD rather than building it, Labcorp leaning on an acquired genetics portfolio to go direct-to-consumer, Edwards waiting on a coverage decision that will do more for volume than any product launch. Scale is the entry ticket now. Everything else is execution.

8 things to watch this week:

1. 🤖 J&J’s Ottava wins FDA De Novo authorization, ending Intuitive’s soft-tissue monopoly

After nearly a decade of delays, J&J secured De Novo marketing authorization for the Ottava Robotic Surgical System across ten general surgery procedures — the first soft-tissue platform to integrate its arms directly into the OR table, occupying 30–50% less space than boom- or cart-mounted systems. J&J is running a controlled launch with select U.S. customers and deliberately entered through general surgery, the less-penetrated segment where Ethicon’s install base and relationships are strongest. Both Intuitive and Medtronic shares declined on the news.

2. ⚰️ Vicarious Surgical shareholders vote to dissolve the company

Shareholders approved an assignment for the benefit of creditors — an alternative to bankruptcy — for a robot developer that raised more than $425 million from investors including Bill Gates ahead of its 2021 SPAC-era IPO. The company failed to secure additional funding or find a buyer and employed 26 people as of March. Same category, same week, opposite outcome: capital depth and channel access are now the gating factors in robotics, not the elegance of the architecture.

MedTech Dive

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🩺 FDA names Dexcom the first participant in its TEMPO digital health pilot

CDRH selected Dexcom as the inaugural manufacturer in the Technology-Enabled Meaningful Patient Outcomes pilot, which pairs device oversight with real-world evidence generation and is explicitly tied to CMS Innovation Center’s ACCESS model — whose first cohort began this month. The Dexcom Glucose Health Program will combine G7 and Stelo data with nutrition, activity, sleep, and stress inputs. FDA says it’s still accepting statements of interest with no deadline, which makes this the clearest regulatory-plus-reimbursement on-ramp available to digital health right now.

MPO Magazine

5. ⚠️ FDA issues early alert as Boston Scientific pulls transcarotid catheter lots

Boston Scientific told customers on July 9 to stop using and return specific lots of the EnRoute Transcarotid Neuroprotection System and NPS Plus after reports of arterial sheath tip separation; the FDA posted its early alert Friday. One serious injury and no deaths have been reported, but retained tips may require endovascular or surgical retrieval, with embolism, stroke, TIA, restenosis, or thrombosis among the potential complications. The device came over in the $1.18 billion Silk Road Medical acquisition — a reminder that acquired product lines carry acquired quality histories.

Cardiovascular Business

6. 💓 Edwards posts strong TAVR quarter with a September coverage decision pending

Edwards raised its full-year outlook on strong structural heart performance, with TMTT revenue up roughly 47% year over year. The bigger catalyst is regulatory: CMS is expected to finalize its TAVR national coverage determination in September, and the draft policy opens a pathway to cover asymptomatic patients while modernizing heart-team requirements. PROGRESS data in moderate aortic stenosis follows at TCT this fall. For anyone modeling structural heart volume, September is the date that matters.

MedTech Dive

7. 🧬 Tempus to acquire Personalis for $1.5B, buying its way into tumor-informed MRD

Tempus agreed to pay $16.25 per share for the cancer-monitoring company, a 6% premium to the prior close and 28% to the unaffected 30-day VWAP, in a deal expected to close in late 2026 or early 2027. The strategic logic is straightforward — Tempus has been commercializing Personalis’ NeXT Personal test since 2023 and its own MRD capability isn’t tumor-informed, the methodology the market is converging on. Both stocks fell on the announcement, largely on the stock-based structure rather than the thesis.

MD+DI

8. 🧪 Labcorp launches a 163-gene direct-to-consumer hereditary risk panel

Marker by Labcorp analyzes 163 genes tied to more than 100 medically actionable conditions across hereditary cancer, cardiovascular, and metabolic categories, with licensed genetic counselors included and availability starting August 3 through Labcorp OnDemand. It’s the company’s first major consumer genetics product since absorbing Invitae’s portfolio in 2024, and Labcorp is explicitly positioning it against curiosity-driven DNA testing. The consumer channel is now a distribution strategy for clinical-grade diagnostics, not a novelty adjacent to one.

Fierce Biotech

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Who Could Afford to Be Late

Within about 24 hours this week, the surgical robotics field delivered two verdicts that read like opposite ends of the same story.

On Tuesday, shareholders of Vicarious Surgical voted to dissolve the company and hand its assets to a creditor trust — an assignment for the benefit of creditors, the orderly alternative to bankruptcy. On Wednesday, the FDA granted De Novo authorization to Johnson & Johnson’s Ottava, clearing the first table-integrated soft-tissue robot for general surgery in the United States.

Both programs ran years past their own timelines. The difference showed up in what happened next.

Vicarious was not a fringe player. Founded in 2014, it went public in 2021 through a SPAC merger that valued it at $1.1 billion, and it raised hundreds of millions from investors that included Bill Gates. Its single-port system — miniaturized arms and a camera threaded through one incision, built to put the surgeon inside the abdomen — was novel enough to become the first surgical robot ever to earn the FDA’s breakthrough device designation.

It also missed, repeatedly. The system slipped against its stated timelines. A planned clinical trial was scrapped. Parts of the design were outsourced to conserve cash. The company lost its NYSE listing earlier this year and moved to the over-the-counter market. When it went looking for fresh capital or a buyer this spring, it found neither. As of early March it employed 26 people. In its final filings, the board told shareholders they were unlikely to receive anything at all — even as terminated executives were set to collect severance packages north of half a million dollars each.

Ottava is the other end. J&J’s robotics ambitions run back through Verb Surgical and the acquisition of Auris Health, and Ottava itself was delayed repeatedly against publicly stated targets. But a parent that just beat $25 billion in quarterly sales does not face a going-concern deadline when a program runs long. It rewrites the date and keeps paying the engineers.

That comparison is worth exactly what it costs, which is not much. Almost nobody reading this is J&J, and “have a $400 billion parent” is not a strategy. The useful case sits between the two, and surgical robotics has already run it.

Asensus Surgical — formerly TransEnterix — hit the same wall Vicarious did. Its Senhance platform was commercial but small, its next-generation Luna system was years from clearance, and cash was the binding constraint. It did not liquidate. In August 2024 it was acquired by Karl Storz for $0.35 a share in cash. The technology found a home; more than 200 employees came along; the buyer talked publicly about accelerating Luna.

Twenty-two months later, Karl Storz ended development of the standalone platform, began phasing out Senhance, retired the Asensus brand, and filed notice of 108 layoffs in North Carolina. What it kept was the software engineering, the clinical data, and the AI work — folded into its own imaging and OR-integration roadmap.

So the three exits are not survive, get rescued, or die. They are: absorb the delay yourself, sell into someone who will decide later which parts of you were worth buying, or liquidate. Only the first is fully in your control, and only the largest companies in the industry have it.

This is the part worth sitting with. Asensus is the good outcome in that set, and the good outcome still ended with the platform discontinued and the brand retired. It preserved the people and the IP. It did not preserve the company’s plan. And the price — thirty-five cents — was set by a buyer who knew exactly how much runway was left on the other side of the table.

For anyone running a capital-intensive program on a regulatory timeline, that reframes the planning question. It is not how long the runway is against the current schedule; the current schedule is the optimistic case, and slippage is the base case, not the downside. The question is what your position looks like at the moment the money gets tight — because that moment is when the exit gets chosen, and whoever has cash at that point sets the terms.

Vicarious had the idea first. Asensus had a buyer. J&J had the room to be late. Three companies, one category, three different answers to the same missed deadline.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🤖 Intuitive’s U.S. procedure growth hits a three-year low — and it’s naming names

Q2 beat on revenue and EPS, but U.S. da Vinci procedure growth slowed to 12% from 14%, and management pointed at two structural culprits: expired ACA enhanced-premium subsidies delaying deferrable surgeries, and GLP-1s pushing bariatric volume down high single digits. The company held its 13.5%–15.5% full-year procedure forecast but guided to the midpoint — and shares dropped double digits, because procedures drive everything downstream in this business model. If insurance-mix softness is real, Intuitive is the canary. Yahoo Finance + 3

MD+DI

2. 🩺 Abbott beats, raises guidance, and shrugs off the ACA worry entirely

Abbott topped Wall Street forecasts and raised full-year adjusted EPS guidance to $5.45–$5.60 — one quarter after cutting it on Exact Sciences dilution, with the March-closed Exact acquisition fueling more than 40% diagnostics growth. The strategic read: diversification is buying Abbott immunity from the exact demand question that just knocked Intuitive down — and management publicly rejected the idea that ACA enrollment declines are materially hurting medtech at all.

MassDevice

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Most medical device companies don't stall because the technology is wrong. They stall because the sequencing is — launching before the market's ready, scaling before the evidence lands, chasing the next milestone before the last one is proven. RŌG Health's Commercial Readiness Check is a short diagnostic that maps where your commercialization actually stands right now, across the gaps that quietly derail otherwise strong programs. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 📉 J&J MedTech growth eases again as Abiomed drags on the quarter

J&J’s device unit posted another quarter of slowing sales growth, with Abiomed weighing on results — a slowdown the company attributed in part to physician response to third-party randomized trial data on Impella. The lesson for every company with a flagship franchise: independent evidence can reprice a market leader’s growth story faster than any competitor can.

Fierce Biotech

5. ⚠️ Medtronic pulls 102 lots of Harmony delivery catheters in Class I recall

Medtronic voluntarily recalled 102 lots of its Harmony delivery catheter system over a distal-tip detachment risk that could require endovascular retrieval or surgery — the FDA’s most serious recall classification, though no serious injuries or deaths had been reported as of mid-May. The valve itself isn’t affected. A reminder that in structural heart, the delivery system carries as much risk exposure as the implant. AOL

Fierce Biotech

6. 🦴 DePuy Synthes buys screwless spine implant maker ahead of its J&J spinout

DePuy acquired Expanding Innovations, whose expandable interbody cages use no screws, on undisclosed terms — strengthening its position in the expandable-cage segment and slotting into the Velys robotic platform as J&J prepares to spin the orthopedics business out. Portfolio-sharpening before a spinout is a familiar playbook: DePuy is building the standalone story it will pitch to public investors.

MedTech Dive

7. 🧠 RapidPulse raises $48M for stroke thrombectomy — with Medtronic co-leading

The Miami-based company closed a Series B for its next-generation aspiration technology for acute ischemic stroke, with Medtronic co-leading alongside TechWald and S3 Ventures. When a strategic co-leads a round in its own core category, read it as an option on future M&A — and a signal of where neurovascular incumbents think the technology curve is bending.

MassDevice

8. 🗓️ FDA hosts Wednesday town hall on human factors guidance — with an August 1 deadline attached

CDRH holds a town hall July 22 on its final guidance covering human factors information in marketing submissions, issued May 29 — and beginning August 1, updated eSTAR templates will prompt manufacturers to identify a Human Factors Submission Category and provide supporting information. If you have a 510(k), De Novo, or PMA in the pipeline, this is the week to get your regulatory team on the same page.

FDA

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Priced Not to Be Seen

The largest penalty ever imposed for dodging a merger filing belongs to the medical device industry as of Monday. The Federal Trade Commission announced a $12 million settlement with Edwards Lifesciences and Genesis MedTech over Edwards’ 2024 acquisition of JC Medical, the Genesis subsidiary developing a transcatheter valve for aortic regurgitation. Under the proposed final judgment, Edwards will pay $10 million and Genesis $2 million — the largest combined penalty in the history of the Hart-Scott-Rodino Act’s filing requirement, according to the agency.

The arithmetic at the center of the complaint is almost elegant. At the time of the deal, any transaction valued above $119.5 million had to be reported to federal antitrust regulators before closing. Edwards agreed to pay $115 million for JC Medical, plus milestone payments — $4.5 million under the line. It also agreed, at the same time, to make a $25 million investment in Genesis itself. Treated as separate transactions, neither required a filing. Treated as what the FTC alleges they were — a single acquisition with the price split across two agreements — the deal cleared the threshold comfortably and should have been reported before it closed.

What happened the next day is why regulators noticed. One day after closing on JC Medical, Edwards moved to acquire JenaValve Technology — JC Medical’s only competitor — for $945 million. That deal was large enough that Edwards had to file. The filing triggered an investigation, the investigation surfaced the structure of the JC Medical purchase, and the FTC sued to block JenaValve on the grounds that Edwards would otherwise own the only two U.S. companies with TAVR-AR devices in clinical trials. In January, a federal court granted a preliminary injunction after a six-day hearing, and Edwards walked away from JenaValve while disputing the ruling. Monday’s settlement closes out the remaining question: what it costs to have skipped the filing in the first place. Edwards and Genesis deny wrongdoing, and the judgment involves no admission of liability.

The money is not the interesting part. Twelve million dollars is a rounding error against Edwards’ balance sheet. The interesting parts are structural, and there are three of them.

First, the seller paid too. Genesis’ $2 million penalty establishes that both sides of a deal structured to avoid review carry exposure — a point antitrust lawyers flagged within a day of the announcement. For smaller companies negotiating an exit to a strategic, how the buyer wants to structure the consideration is no longer only the buyer’s problem.

Second, Edwards now operates under a bespoke leash. The judgment requires advance written notice to the FTC before Edwards acquires any interest in any firm that sells a TAVR-AR device in the U.S., is running U.S. clinical trials on one, or holds an investigational device exemption to start. In an entire category, Edwards has lost the thing every acquirer of sub-threshold companies takes for granted: the ability to close quietly.

Third, the timing. This lands in the middle of a running boom in medtech dealmaking — the strongest first half for sector M&A since 2022, by BioWorld’s tracking — much of it composed of exactly the kind of tuck-in acquisitions that fall below the reporting line. The threshold adjusts annually and most small deals will keep closing without review. But the substance-over-form logic here — that a side investment, a milestone schedule, or any contemporaneous consideration counts toward the real price — is now backed by a record penalty and a chairman promising that companies who “sneak deals through” should take notice.

For device companies on either side of an acquisition, the operative lesson is that the threshold was never a safe harbor. It was a reporting line. The FTC just demonstrated it knows the difference — and that it may learn about your last deal from your next one.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Two of the industry’s biggest names spent the week reshaping their portfolios in opposite directions — Roche muscling into sequencing, ResMed shedding software to fund its core — while the reimbursement map shifted underneath everyone with a sweeping CMS proposal and a landmark payer win for blood-based cancer screening. The counterweight was risk surfacing where the giants are most exposed: a Terumo aortic recall tied to three deaths, and Medtronic’s breach notification reaching nearly four million people. The throughline for operators: the same reach that drives growth now defines the downside, and quality systems, reimbursement strategy, and data governance are moving from back-office concerns to boardroom ones.

8 things to watch this week:

1. 🧬 Roche takes on Illumina with new NGS system

Roche launched Axelios 1, its long-teased sequencing platform built on new “sequencing by expansion” chemistry, priced at roughly $750K against Illumina’s NovaSeq X and targeting research labs first with a clinical path to follow. More than a decade after its failed hostile bid for Illumina, Roche is attacking the $7.3B market on price and speed rather than head-on — a reminder that in a mature category, the entry strategy matters as much as the technology.

Fierce Biotech

2. 💨 Resmed to sell software business MatrixCare for $490M to private equity firm

Resmed agreed to offload MatrixCare — a $220M-revenue post-acute EHR business it bought for $750M in 2018 — to Frazier Healthcare Partners, redirecting capital toward sleep, breathing, and connected home care. It’s a clean case study in portfolio discipline: a mature, slower-growing asset carved out so the core can compound faster, with proceeds funding buybacks rather than new bets.

MedTech Dive

3. 🧭 Where does your commercialization actually stand? Two minutes to find out.

Most medical device companies don't stall because the technology is wrong. They stall because the sequencing is — launching before the market's ready, scaling before the evidence lands, chasing the next milestone before the last one is proven. RŌG Health's Commercial Readiness Check is a short diagnostic that maps where your commercialization actually stands right now, across the gaps that quietly derail otherwise strong programs. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🏛️ CMS targets 340B, site-neutral pay in 2027 outpatient rule

The CMS 2027 OPPS/ASC proposed rule, issued July 2, would deepen 340B drug payment cuts and push site-neutral payment into new outpatient categories — moves projected to pull billions from hospital outpatient revenue starting in 2027 and affecting roughly 3,500 hospitals and 6,400 ASCs. Device leaders should read the site-neutral expansion as a signal: as reimbursement flattens across care settings, the economics of where a procedure is performed — and who buys the device — are being rewritten. Comments close August 31.

Becker’s Hospital Review

5. ⚠️ Terumo initiates voluntary thoracic stent graft recall after 3 deaths

Terumo recalled roughly 7,000 RelayPro thoracic stent-grafts across 43 countries after four cases in which physicians couldn’t separate the delivery system from the deployed graft — three of which ended in patient deaths. Terumo hasn’t established direct causation but suspended shipments in March and has now expanded the action globally, a sharp reminder that delivery-system failures, not just the implant, sit squarely inside post-market risk.

MassDevice

6. 🔓 Major medical device manufacturer notifies nearly 4 million of breach

Medtronic began notifying nearly four million people that April’s ShinyHunters intrusion into its corporate IT systems exposed names, dates of birth, Social Security numbers, and health-related data — details that surfaced via a California AG notification filing. The company maintains device safety and operations were unaffected, but the notification scale underscores how patient-data liability now travels with any connected-device franchise, independent of clinical risk.

The Record

7. 🫀 Edwards Lifesciences crashes the LAA party — can the TAVR giant compete?

Edwards won 510(k) clearance for Ecliptis, its left atrial appendage exclusion clip, entering a crowded surgical LAA market against AtriCure’s AtriClip and Medtronic’s Penditure. Edwards is betting its structural-heart surgical relationships carry into a new therapeutic area — a textbook adjacency play whose success will hinge less on the device than on whether an established commercial channel actually transfers.

MD+DI

8. 🩸 Guardant’s Shield colon cancer blood test snags UnitedHealth coverage

UnitedHealth became the first major private U.S. insurer to reimburse Guardant’s Shield blood-based colorectal screening test, extending access to roughly 100 million people — a decision one analyst called a “watershed moment” for liquid biopsy. Notably, coverage arrived ahead of USPSTF inclusion, a reversal of the usual sequence that suggests commercial payers may increasingly move on category conviction rather than waiting for guideline consensus.

MedTech Dive

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The Fine Print on the Next Five Years

The medical device industry got its first look this week at the contract it will operate under through 2032. On Tuesday, the FDA posted the draft MDUFA VI commitment letter — the 36-page product of nearly a year of negotiations between the agency, AdvaMed, and the Medical Device Manufacturers Association over what industry user fees will buy in the sixth iteration of the device user fee program. The Federal Register notice followed Wednesday, opening a comment docket that closes July 29.

On paper, industry got much of what it asked for. The letter commits the agency to a new fast lane for pre-submission questions — written responses within 45 calendar days for focused follow-ups, launching by the end of 2027. De novo applicants would get a structured introduction meeting with reviewers inside the first 30 days of review. Major deficiency letters, a longstanding industry complaint, would require supervisory sign-off and a complete review before issuance. The TAP pilot graduates into a permanent program with hard metrics attached, including facilitated CMS engagement for devices that need new coverage determinations. And 510(k) decision targets start at an average of 128 calendar days for fiscal 2028 submissions, stepping down to 112 days by 2032.

The most quietly radical item is an international harmonization pilot slated for the end of fiscal 2028: a device submitted simultaneously to the FDA and at least two other regulatory authorities could get a coordinated review, with the agency leveraging elements of its counterparts’ assessments. The FDA retains final authority, and reliance is limited to an “abridged approach” — but an agency that has spent decades positioning itself as the global gold standard is now formalizing a mechanism to lean on other regulators’ work. That is a meaningful philosophical concession to resource reality.

Which is the tension running through the entire document. Every performance goal in the letter carries a conditional clause — the targets hold, the FDA writes, “provided that the total funding of the device review program adheres to the assumptions” underlying the agreement. That hedge is doing heavy lifting. This letter arrives at an agency that cut more than 3,000 roles last year and is now trying to hire 2,000, and it lands one week after BTIG data showed average PMA approval times reaching nearly 599 days in the first half — up from roughly 402 a year earlier. The agency is committing to move faster over the next five years at the precise moment its measured performance is moving in the other direction.

AdvaMed CEO Scott Whitaker welcomed the draft, framing it as delivering the stability and predictability innovators need. That’s the right corporate posture, and it’s also the industry’s real stake here: for companies planning submissions into 2028 and beyond, these targets are the planning assumptions that capital runways, launch calendars, and hiring plans get built on. A 128-day 510(k) average and a 45-day pre-sub lane are not abstractions — they’re inputs to every regulatory-timeline slide in every board deck for the next half decade.

The path from here is fixed: a public hybrid meeting on August 5, a final commitment letter to Congress by January 15, 2027, and enactment required by September 30, 2027, when MDUFA V expires. The window for the industry to shape the terms — or flag where the assumptions look shaky — is the next three weeks. After that, the fine print becomes the contract.

SPONSORED BY RŌG HEALTH

Where does your commercialization actually stand?
Two minutes to find out.

Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The throughline this week is a widening gap between what the FDA clears and what actually reaches patients. New mid-year data show device authorizations rising even as approval timelines stretch out; a STAT investigation puts hard numbers on how many “breakthrough” devices never make it to market; and a GAO probe flags recall oversight buckling under staff constraints. Meanwhile, the M&A machine keeps running — Zimmer’s tuck-in of Pacira’s iovera device shows strategics are still paying up for assets that fit a clear commercial channel, especially anything riding the non-opioid pain tailwind. The operator’s takeaway: clearance is table stakes; the real gating factors are timing, coverage, and post-market discipline.

8 things to watch this week:

1. 🧊 Zimmer Biomet to buy Pacira’s iovera pain device for up to $140M

Zimmer agreed to pay $70M upfront plus up to $70M in revenue-based milestones through 2031 for iovera, an FDA-cleared cryoneurolysis device that blocks pain by freezing targeted nerves. The deal slots neatly into Zimmer’s orthopedics channel and rides the tailwind of last year’s non-opioid pain legislation — a clean example of a strategic buying a commercial-ready asset that fits an existing salesforce rather than a moonshot.

MedTech Dive

2. ⏱️ FDA is authorizing more devices in 2026 — but taking longer to do it

A mid-year BTIG analysis found the FDA cleared more devices in the first half than a year ago, but average time to premarket approval ballooned to nearly 599 days from about 402. For smaller companies, that timing gap hits capital runway and demand forecasting harder than the approval itself — a reminder that “cleared eventually” and “cleared on schedule” are very different business cases.

MD+DI

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

Before you raise, launch a pilot, or scale revenue, small commercialization mistakes can cost months — or millions. RŌG Health's Commercial Readiness Check is a 2-minute diagnostic that shows whether your company is prepared for its next milestone, and points you to where the gaps are.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🫀 What an abandoned heart-failure trial reveals about ‘breakthrough’ devices that never reach patients

STAT dug into LivaNova’s discontinued VITARIA vagus-nerve-stimulator trial to make a broader point: the majority of devices granted FDA breakthrough status are never authorized, and it’s rare to learn why. The piece is a useful corrective to the marketing shine around the breakthrough label — designation speeds review, but it’s no guarantee of a finish line, and the industry rarely gets to see the failures.

STAT

5. 🔍 GAO finds understaffed FDA putting some device recall work on the ‘back burner’

A Government Accountability Office report concluded the FDA’s recall oversight is beset by staffing shortfalls and slow response times, with the agency managing roughly 900–1,000 device recalls a year — three times the volume of drug or biologic recalls. GAO also flagged that the FDA hasn’t done fresh workforce planning amid ongoing departmental restructuring. For quality and regulatory leaders, it’s a signal that post-market timelines may get less predictable, not more.

Fierce Biotech

6. 💳 CMS and FDA roll out RAPID pathway to speed Medicare coverage for breakthrough devices

The administration unveiled a RAPID coverage pathway granting permanent Medicare coverage for qualifying breakthrough devices tied to IDE studies enrolling Medicare beneficiaries, while pausing the existing TCET program. CMS estimates roughly 40 devices could qualify now, with about 20 more eligible. Coverage-after-clearance has quietly become the industry’s bigger bottleneck than FDA review itself — this is the reimbursement side finally getting attention.

Fierce Healthcare

7. 📈 Medtech M&A holds its momentum after a decade-high 2025: PwC

PwC’s mid-year read found deal volumes and values tracking above the first half of 2025, powered by Boston Scientific’s Penumbra buyout and Danaher’s Masimo close — but with disclosed value concentrated in a handful of large transactions. The nuance worth flagging: as strategics scale, mid-size deals increasingly go undisclosed, so the visible headline numbers understate how broad the activity really is.

MedTech Dive

8. 🩸 FDA approves first gene therapy for young children with sickle cell disease

The agency cleared its first gene therapy indicated for young children with sickle cell disease, extending a one-time treatment approach into a pediatric population. It sits just outside the device lane, but it’s a marker worth tracking: the FDA’s willingness to push durable, high-cost one-time therapies into younger patients reshapes the coverage and durability questions that device makers in adjacent chronic-disease categories will face next.

FDA

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The FDA Is Saying Yes More Often. It's Just Taking Much Longer to Get There.

Halfway through 2026, the medical device industry got a data point that cuts two ways at once. The FDA is clearing and approving more devices than it did a year ago — more premarket approvals, more panel-track supplements, more 510(k)s on pace than 2025. By the crude measure most people reach for first, the agency is more productive than it was.

Then you look at the clock.

According to a mid-year analysis of FDA’s device databases by BTIG analyst Ryan Zimmerman, the average time to an original premarket approval — the agency’s most stringent review, reserved for its highest-risk devices — stretched to roughly 599 days in the first half of 2026, up from about 402 days over the same period last year. That is nearly seven additional months of waiting for the companies whose products sit at the top of the risk pyramid. The volume is up; the wait is up more.

The number deserves a caveat, and it’s an important one. Zimmerman flagged that a handful of long-delayed approvals finally crossed the finish line in the first half — three outliers that had been stuck in the pipeline for years and dragged the average sharply upward. Strip those three out, and the average time to PMA approval falls to about 339 days, which would actually be an improvement over last year. So the headline figure is real but distorted: the typical device isn’t waiting 599 days. The system cleared a backlog, and the backlog is showing up in the math.

But the softer signals point the same direction as the scary one. The average 510(k) decision — the workhorse pathway that carries the vast majority of devices to market — slipped to about 156 days, a 5% increase over 2025. De novo classifications took roughly 8% longer. Panel-track approvals, up nearly 17% in volume, still took 6.5% longer each. Across nearly every pathway, the pattern holds: more throughput, slower clocks.

For a large diversified manufacturer, a few extra weeks or months is an annoyance to be managed. For a venture-backed company with one product and eighteen months of cash, it is the whole ballgame. Zimmerman made the point plainly: the absolute level of approvals is encouraging, but for many in the industry — and for smaller companies in particular — the timing to approval carries more weight, because it dictates capital runway and demand forecasting. An approval that arrives a quarter late can mean a bridge round raised on worse terms, a commercial launch pushed into a different budget cycle, or a sales forecast that has to be rebuilt from scratch.

The context behind the slowdown isn’t a mystery. The device center spent the past year absorbing significant staff reductions — more than 3,000 roles cut — and is now trying to hire back upward of 2,000 people. The reviewers who stayed have been carrying heavier caseloads through the transition. A center can clear more submissions and still take longer on each one when it’s running short-handed against a growing queue — that’s not a contradiction, it’s what a strained pipeline looks like from the outside.

The strategic read for device leaders is less about the exact day count than about what to assume when you build the plan. For anyone modeling a submission this year, the prudent move is to treat the review clock as a variable that has widened, not a fixed input carried over from a smoother year — and to know which pathway you’re in, because the pain isn’t evenly distributed. The 510(k) drift is modest. The high-risk PMA and de novo routes are where the timeline risk is concentrated, and those are exactly the routes the most novel, most capital-intensive products travel. The agency is saying yes more often. Planning around when it will say yes is the harder problem this year.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III commercialization happen before launch — raising on a story that doesn’t hold, hiring before positioning is set, going to market before the buyer is clear.

RŌG Health’s Commercial Readiness Check is a free, two-minute assessment that shows you where your commercial readiness is strongest, where you’re most exposed, and which RŌG diagnostic fits where you are.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

This week’s signal sits at the intersection of consolidation and discipline. The robotics shakeout claimed another platform as Karl Storz pulled the plug on its Asensus inheritance, while H.B. Fuller’s move into surgical adhesives showed deal appetite is reaching well outside the usual medtech roster. Underneath the M&A, the post-market story kept its grip: a fresh bleeding-risk alert and the still-reverberating Zoll warning letter are reminders that quality systems, not technology, remain the industry’s exposed flank. And in diabetes, the sensor wars went transatlantic.

8 things to watch this week:

1. 🤖 Karl Storz scraps Asensus robotics platform, cuts 108 jobs in North Carolina

Two years after acquiring Asensus to advance its next-gen Luna robotic system, Karl Storz is discontinuing Luna development, phasing out the Senhance platform, and retiring the Asensus brand entirely, with layoffs including roughly 30 engineers. The reversal is a stark signal that even well-funded soft-tissue robotics programs are struggling to find a path against Intuitive’s entrenched lead — and that “robotics as a layer” is winning over robotics as a standalone bet.

MedTech Dive

2. 🩸 MiniMed launches Abbott-made Instinct sensors across Europe

The newly independent MiniMed rolled out its 780G and Go systems paired with Abbott’s 15-day Instinct sensor in Europe, opening its pump franchise to roughly 4.5 million Abbott CGM users it previously couldn’t reach. The Medtronic-Abbott collaboration is a notable détente between two diabetes-tech rivals — and a reminder that, with 70% of MiniMed’s sales coming from overseas, the European installed base is the real battleground.

Drug Delivery Business News

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

Before you raise, launch a pilot, or scale revenue, small commercialization mistakes can cost months — or millions. RŌG Health's Commercial Readiness Check is a 2-minute diagnostic that shows whether your company is prepared for its next milestone, and points you to where the gaps are.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🔬 Diabetes-tech execs weigh the promise and problem of multi-analyte sensors

Leaders from Abbott, PercuSense and Biolinq laid out where continuous sensing goes next — beyond glucose to ketones, lactate and potassium — on the heels of Abbott’s CE mark for its dual glucose-ketone Libre Duo. The strategic tension is data, not chemistry: each new analyte generates a stream that clinicians and payers don’t yet have workflows to act on, raising the question of who owns the burden of interpretation.

MedTech Dive

5. 💰 H.B. Fuller bids ~$942M for surgical-adhesives maker Advanced Medical Solutions

The world’s largest pure-play adhesives company agreed to a £715M ($942.5M) cash takeover of UK-listed AMS, adding tissue bonding adhesives, dressings and biosurgicals and expanding its addressable market by $15B. It’s a telling sign of where the smart money sees durable margins: an industrial player paying a 35% premium to buy its way into the regulatory-moated medical segment rather than build.

Medical Device Network

6. 💲 Medtronic names its first-ever CFO of innovation

Medtronic hired 22-year J&J veteran Eric Lenard into the newly created role of VP and CFO for innovation, development and quality, putting finance leadership directly inside the R&D engine. The move — amid a year of restructuring including the MiniMed spinoff and a new Ireland software hub — signals an attempt to bring capital-allocation discipline to the pipeline as the company pivots to “offense” on M&A.

MassDevice

7. ⚠️ J&J’s Abiomed warns of bleeding risk in catheter-introducer devices

Abiomed and manufacturing partner Oscor flagged a bleeding risk tied to devices used to introduce catheters into the body — the latest in a long string of post-market actions touching J&J’s circulatory-support franchise. For operators, the cadence of alerts around high-acuity cardiac devices keeps the spotlight on supplier quality and vigilance reporting as the real differentiators.

Cardiovascular Business

8. 🏭 Zoll’s FDA warning letter exposes a years-long CAPA breakdown

The FDA’s warning letter to Zoll detailed how a ventilator nonconformance coded as “user error” delayed a Class I recall by weeks, with the agency citing repeated inadequate responses across nearly a year. Notably, the FDA reminded Zoll that corrective actions must now comply with the QMSR that took effect February 2 — a preview of how the new quality framework will be enforced against legacy violations.

MD+DI

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The Company That Said No: What Whoop's FDA Win Teaches About Holding the Line

A year ago, the conventional read on Whoop’s situation was that it had one move left. In July 2025, the FDA had sent the Boston wearable maker a warning letter arguing that its Blood Pressure Insights feature — daily systolic and diastolic estimates derived from heart rate and blood-flow patterns during sleep — made the device a medical product requiring premarket review. Blood pressure, the agency wrote, is inherently tied to the diagnosis of hypertension. The standard playbook said: pull the feature, file for clearance, wait.

Whoop didn’t. CEO Will Ahmed posted publicly that the company wouldn’t let “regulatory overreach dictate how people access their own health data,” kept the feature live, and negotiated. Last week, the standoff ended on Whoop’s terms. In a closeout letter dated June 17, the FDA said it does not intend to enforce device requirements against the feature as modified. The modifications were modest: Whoop is reworking the display from a dial with color-coded boundaries — which implied clinical categories — into a continuous green-to-red gradient with no discrete classifications. The underlying measurement didn’t change. The framing did.

For device leaders, the easy lesson is the wrong one. This is not a story about a wearable’s blood-pressure math. It’s a story about regulatory posture as a strategic asset — and about how much the ground has shifted under the wellness/medical-device boundary in eighteen months.

Consider the sequence. Whoop received its warning letter in July 2025. The following January, the FDA issued updated guidance clarifying that wearable features estimating biometrics like blood pressure need not be regulated as devices when framed for wellness — provided they avoid disease claims and don’t characterize outputs as abnormal, pathological, or diagnostic. The closeout letter explicitly cites that guidance as part of its rationale. In other words, the company that drew the enforcement action outlasted the policy that justified it. As Carrie Nixon, who advises digital-health companies, told STAT, Whoop’s decision to engage rather than capitulate “may have shaped the regulatory landscape for the entire wearables industry.”

That is the part worth sitting with. A single company’s refusal to fold became a forcing function on agency policy, and the policy then resolved the company’s case in its favor. For operators, it reframes what a warning letter is. Under the prior orthodoxy, an enforcement letter was a verdict. Here it functioned more like an opening position — one a well-capitalized company with a defensible scientific argument and public conviction could negotiate against over a year-plus horizon.

The opportunity this opens is real, and so is the trap. The wellness lane is now demonstrably wider: the same sensor stack can be routed toward wellness framing or medical claims depending on labeling, UI, and intended-use language. Whoop’s own fix — recoloring a dial — shows how much of the regulatory distinction now lives in presentation rather than function. The FDA’s January guidance made clear that intended use is read through the interface and the way data is shown to users, not just the formal claims in a submission.

But the same softness that creates the lane creates exposure. The guidance update unleashed a wave of wellness blood-pressure features from the likes of Oura and Samsung, and the underlying PPG sensor technology cannot reliably estimate blood pressure — the FDA has cleared only a handful of cuffless PPG devices, in at least one case only with mandatory daily cuff calibration. Duke biomedical engineer Jessilyn Dunn, whose team published a critique this week of the agency’s ambiguous validation expectations, warned that placing the burden on the market to sort trustworthy from untrustworthy products invites patient harm and erodes confidence in the whole category. People act on these numbers regardless of the disclaimers.

So the strategic read for a device leader is two-sided. The regulatory environment now rewards conviction and punishes premature capitulation more than it did a year ago — if your scientific argument is sound and your framing is disciplined, holding the line is a live option, not a fantasy. But the same permissiveness that let Whoop win also lets weaker products in, and the first serious patient-harm story tied to an unvetted wellness feature will test how durable this lane really is. Whoop spent its credibility carefully and bought room to operate. The companies now rushing into the space behind it are spending against an account they didn’t fund.

The line moved. The question every consumer-health hardware company should be asking is not whether they can now make the claim, but whether they can defend it when the line moves back.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III commercialization happen before launch — raising on a story that doesn’t hold, hiring before positioning is set, going to market before the buyer is clear.

RŌG Health’s Commercial Readiness Check is a free, two-minute assessment that shows you where your commercial readiness is strongest, where you’re most exposed, and which RŌG diagnostic fits where you are.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The week’s throughline was a split screen. On one side, regulators tightened the screws — Zoll caught a multi-count warning letter, and a closely watched neuro-oncology device missed its endpoint, a reminder that even well-capitalized late-stage programs aren’t safe bets. On the other, the AI-enabled clearance pipeline kept moving, with Masimo, Sanofi, and others pushing pattern-recognition and detection tools into commercial settings. The takeaway for operators: quality-system discipline and clinical proof are becoming the real gating factors, not the technology itself.

8 things to watch this week:

1. ⚠️ FDA warning letter hits Zoll Medical over quality-control and reporting failures

The FDA slammed Asahi Kasei-owned Zoll Medical with a warning letter citing multiple quality-system and adverse-event reporting violations. For any device maker, it’s a sharp reminder that post-market compliance — not just premarket clearance — is where regulatory risk increasingly concentrates.

Fierce Biotech

2. 🧠 Novocure’s tumor-treating device fails Phase 3 brain cancer survival endpoint

Novocure’s Optune device did not meaningfully improve survival in a pivotal brain cancer trial, a setback for the company’s expansion ambitions. The miss underscores how high the clinical bar remains for novel modalities trying to move beyond their initial approved indications.

Fierce Biotech

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

Before you raise, launch a pilot, or scale revenue, small commercialization mistakes can cost months — or millions. RŌG Health's Commercial Readiness Check is a 2-minute diagnostic that shows whether your company is prepared for its next milestone, and points you to where the gaps are.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🫁 Masimo wins FDA clearance for AI-enabled opioid-induced respiratory depression detection

Now a Danaher company following this month’s $10B acquisition, Masimo cleared an AI pattern-recognition feature for its Radius VSM wearable monitor that flags early signs of respiratory compromise in patients on opioids. It’s an early signal of how Danaher intends to monetize Masimo’s monitoring platform inside hospitals.

MassDevice

5. 🩸 Dexcom wins FDA clearance for first over-the-counter CGM for children

The FDA cleared Dexcom’s Stelo biosensor for non-insulin users as young as two, the first OTC continuous glucose monitor indicated for kids. Notably, the agency leaned on real-world evidence rather than a dedicated pediatric trial — a quiet but important signal about the evidentiary pathways now open to device makers.

MobiHealthNews

6. 🇪🇺 EU confirms AI medical devices stay under dual AI Act and MDR compliance

A political agreement on the Digital Omnibus confirmed that AI-enabled devices will face parallel compliance under both the AI Act and MDR/IVDR — a blow to industry groups that lobbied for sector-specific rules. Parliament estimates the overlap could cost the industry up to €3.3B annually, a real planning factor for anyone with European ambitions.

Healthcare Digital

7. 🏭 Inside Johnson & Johnson’s new $1B U.S. manufacturing investment

J&J committed $1B to expand its Jacksonville, Florida operations, joining a wave of medtech and pharma giants reshoring production amid tariff pressure. For mid-tier players, it’s a signal that domestic manufacturing capacity — and the supply-chain resilience it buys — is becoming a competitive line item, not just a cost center.

MD+DI

8. 💰 Med-tech M&A hits $63B through five months — but May dealmaking ran thin

Year-to-date med-tech deal value reached $62.98B, the highest five-month total since 2022 — but the figure was driven by a handful of large early-year transactions, with May itself contributing just $970M. The split tells operators that capital is concentrated in a few marquee deals, not broad-based buying, so positioning to be one of the few targets that matters more than ever.

BioWorld

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

When One Supplier Is the Whole Market: What a Breast Biopsy Needle Shortage Tells Device Leaders About Concentration Risk

The week’s louder medtech headlines were about growth — Distalmotion adding gynecology indications, Penumbra’s clot-removal nod feeding Boston Scientific’s pipeline, M&A momentum that PwC says is still running hot off a decade-high 2025. Then, quietly, on a Tuesday, the FDA sent a letter to the country’s breast imagers telling them to ration.

The agency now expects the shortage of stereotactic breast biopsy needles to run through the end of March 2027 — a full year past the point it first added the product code to its device shortage list in March. The recommended fixes read less like clinical guidance than like wartime quartermastering: diversify gauges and lengths, expand supplier networks, centralize inventory dashboards across imaging sites, limit “unnecessary opening” of devices. The agency is, in effect, asking radiologists to manage a commodity the way a factory manages a component that suddenly went sole-source.

That word — sole-source — is the story device leaders should sit with, because it isn’t really about needles.

The proximate cause traces to a single product. In January, Hologic pulled all lots of the 9-gauge disposable needle used in its Brevera Breast Biopsy System after determining that metal and plastic particles could break off during the procedure and lodge in tissue. The failure mode is the kind that should focus any quality team: the company’s own review of nearly 700,000 needles over three years surfaced 108 complaints, and the FDA has logged roughly 20 adverse event reports this year alone — including a patient who returned five months post-biopsy to find that the lump she felt was a four-centimeter fragment of plastic tubing left behind along the needle path.

Here is the part worth dwelling on. The Brevera recall was a single-product action by a single manufacturer. It should have been absorbable. Instead it became a national diagnostic bottleneck, because the alternatives could not soak up the displaced demand fast enough. The American College of Radiology, which spent the spring pressing the agency to coordinate a response, put it plainly: limited alternatives have not fully met clinical demand, and the strain has rippled across the supply chain. When one company’s stop-ship can delay cancer diagnoses across an entire procedure category, the market was more concentrated than anyone priced in.

For Hologic, the timing compounds the pain. The company runs a breast-health franchise worth roughly $1.5 billion in annual sales, went private this spring in a deal backed by Blackstone and TPG, and is trying to claw back supply by expanding manufacturing shifts and re-tooling Brevera to run as a standalone imaging unit. Analysts have read the extended shortage as quietly erasing contingent-value-right payouts that were already largely written off. A quality problem migrated, on schedule, into a commercial and financial one — the sequencing failure mode in its purest form.

But the harder lesson is for everyone who doesn’t make biopsy needles. Most device companies model competitive risk and regulatory risk with some discipline. Concentration risk — the quiet fact that a category’s resilience depends on whether a second credible supplier can scale on short notice — tends to live in a footnote until the day it doesn’t. The companies that will navigate the next eighteen months well are the ones treating the FDA’s conservation memo not as someone else’s problem but as a stress test: if our product vanished from the market tomorrow, is there a second source that could actually absorb the demand, or are we one recall away from being the bottleneck?

The needles will come back. Hologic says it aims to return them to market by the end of 2026, and the FDA is evaluating mitigations. What won’t reset as cleanly is the reminder, delivered in the dry register of a letter to health care providers, that a market can look competitive right up until the moment a single supplier blinks.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III commercialization happen before launch — raising on a story that doesn’t hold, hiring before positioning is set, going to market before the buyer is clear.

RŌG Health’s Commercial Readiness Check is a free, two-minute assessment that shows you where your commercial readiness is strongest, where you’re most exposed, and which RŌG diagnostic fits where you are.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

8 things to watch this week:

1. 🫀 Edwards wins FDA approval for the first dedicated surgical tricuspid valve

Edwards secured approval for Triformis Resilia, the first surgical valve designed specifically for the tricuspid position — and notably, the FDA cleared it without a pivotal trial, relying on a retrospective analysis of real-world off-label use data pulled from EHRs. A meaningful precedent for how evidence packages may be assembled for underserved indications.

MedTech Dive

2. 🧭 FDA expands 510(k) exemptions for the first time since 2019

The agency added five product codes to its list of unclassified devices exempt from premarket notification, bringing the total to 13, and implemented the guidance without prior comment. Part of a broader “less burdensome” posture worth tracking if any of your products sit near these boundaries.

MD+DI

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

Before you raise, launch a pilot, or scale revenue, small commercialization mistakes can cost months — or millions. RŌG Health's Commercial Readiness Check is a 2-minute diagnostic that shows whether your company is prepared for its next milestone, and points you to where the gaps are.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🧬 Medtronic closes $550M Scientia Vascular acquisition

Medtronic completed its purchase of the Salt Lake City–based maker of neurovascular access products, joining Boston Scientific (Penumbra) and Stryker (Inari) in the rush to build out stroke-treatment portfolios. Neurovascular is fast becoming the segment everyone wants a position in.

MassDevice

5. 📊 FDA to accept de-identified real-world evidence for select device applications

The agency is dropping the requirement for identifiable individual data in certain device submissions, extending its broader shift toward real-world evidence and new approach methodologies. Paired with the Edwards approval above, the direction of travel on evidence standards is hard to miss.

AJMC

6. 💰 Abbott and Mayo Clinic anchor Star51 Capital’s debut $100M medtech fund

Star51 closed the first tranche of a $100M fund targeting early- and growth-stage companies at the convergence of medtech and AI — spanning interventional therapies, diagnostics, monitoring, and digital health. Strategic-and-provider-anchored capital entering the early-stage market is a useful signal about where the smart money expects the next wave of devices to originate.

FirstWord HealthTech

7. 🩺 Biotronik performs first U.S. implant of its LivIQ leadless pacemaker

The first U.S. case in Biotronik’s BIO-LivIQ pivotal trial puts a third serious player into leadless pacing — its single-device design delivers AV synchrony via atrial far-field sensing, something it says no other intracardiac pacemaker does. With 325 patients planned across 60 sites, it’s a direct challenge to the Abbott–Medtronic duopoly.

Cardiovascular Business

8. 🔧 Medtronic earns CE mark for its Stealth AXiS surgical platform in ENT

Medtronic extended its next-generation ENT navigation-and-robotics platform into Europe, following U.S. clearance earlier this year. Built on its Mazor and StealthStation lineage and designed for both hospitals and ambulatory surgery centers, it’s another step in robotics, pushing past soft-tissue surgery into adjacent specialties.

MPO Magazine

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The Loop Is Closing — and Diabetes Is Showing the Rest of Medtech What That Costs

In New Orleans last weekend, the diabetes-technology field stopped arguing about whose sensor is more accurate and started arguing about something harder: how much of the patient you can remove from the loop entirely.

That was the through-line of the American Diabetes Association’s 86th Scientific Sessions, held June 5–8. Insulet, Dexcom, Medtronic’s MiniMed, Tandem, Beta Bionics, and a clutch of smaller entrants each brought data, but the data all pointed the same direction — toward systems that sense a physiological signal and act on it without a human deciding anything in the moment. Insulet’s STRIVE pivotal trial and EVOLUTION 3 feasibility study were the clearest statement of the thesis: the company’s investigational fully closed-loop system for type 2 diabetes adjusts insulin “with no user settings,” and its EVOLUTION 3 cohort reached 64% time in range from a baseline A1C of 8.1%. MiniMed’s chief product and technology officer told MedTech Dive that, having watched the competition’s results at the meeting, his team is “clearly ahead” in the same race.

The phrase doing the work is fully closed loop — no carb counting, no meal announcements, no dosing math. It is a deliberate step beyond today’s hybrid systems, which still ask the user to tell the device when they’re about to eat. And it is, notably, a product category that does not yet exist commercially. Insulet’s incremental Omnipod 6 — which improved time in range to 77% for type 1 and 76% for type 2 users versus 73% on the current Omnipod 5 — is slated for next year, but its fully closed-loop type 2 system isn’t expected to launch until 2028, with a 510(k) filing planned for 2027. MiniMed is roughly halfway through enrollment in its own pivotal trial. The field is committing capital, trial infrastructure, and public narrative to a category whose proof and reimbursement are still years out.

For readers whose beat isn’t diabetes, that is the part worth sitting with. Diabetes is not a special case here; it is the leading indicator. It arrived at autonomy first because it has the two ingredients that make a closed loop tractable: a single variable you can measure continuously and a single output you can titrate. Once a field has both, the basis of competition migrates predictably — from is the measurement right? to how much of the human can we take out? Any device category approaching sensor maturity is on the same path.

Cardiovascular and neurological device makers are already on it. Earlier this year, Medtronic won FDA approval for BrainSense Adaptive Deep Brain Stimulation, the first closed-loop DBS system, which senses brain signals and adjusts its own therapy without a clinician intervening — and more than 1,000 patients have already received it. A growing body of work in closed-loop autonomic neuromodulation is pushing the same sense-and-respond logic into heart failure and arrhythmia management, building on devices like CVRx’s Barostim. The diabetes field is simply further down a road that cardiology, neurology, and others are now entering.

Which is why the costs diabetes is paying now are the costs those fields should be pricing in. Three travel across every vertical. First, autonomy is a reimbursement and liability problem before it is an engineering problem — the diabetes companies are pre-announcing years ahead of coverage because payers and the FDA have no settled framework for “the device decided.” Second, the hardest moat isn’t the algorithm; it’s trust transfer — persuading a clinician to cede a judgment call they were trained to own. Third, autonomy reshapes the market beyond the original patient. Dexcom’s CONNECT trial, the first Level A evidence for continuous glucose monitoring in type 2 patients not on insulin, posted a 0.9-percentage-point greater A1C reduction than routine care — and in doing so argued that a tool built for the most acute users belongs with a far larger, lower-acuity population. As Fierce Biotech noted, that population is the next battleground.

The open question for the industry is not whether the loop closes. It is whether the evidentiary, regulatory, and trust structures mature fast enough to meet the devices when they arrive. Diabetes is running the experiment in public. Everyone else should be taking notes.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III commercialization happen before launch — raising on a story that doesn’t hold, hiring before positioning is set, going to market before the buyer is clear.

RŌG Health’s Commercial Readiness Check is a free, two-minute assessment that shows you where your commercial readiness is strongest, where you’re most exposed, and which RŌG diagnostic fits where you are.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The week’s signal sits in two places. Diabetes tech dominated the news cycle out of ADA, with three of the major players posting pivotal data or label expansions and a notable tuck-in acquisition. Underneath that, a fresh wave of recalls and warning letters kept landing on quality systems and sterility — not core technology — a reminder that post-market exposure is where well-funded device makers are still getting caught. Capital kept moving regardless; M&A hasn’t cooled.

8 things to watch this week:

1. 🩸 Insulet posts pivotal Omnipod 6 and fully-closed-loop data at ADA

Insulet’s STRIVE pivotal trial showed improved glucose control with the next-gen Omnipod 6 versus Omnipod 5, while its EVOLUTION 3 study of a fully closed-loop system for type 2 diabetes lifted time-in-range to 64% and cut daily insulin from 86 to 58 units with no weight gain. A 2027 FDA filing and 2028 launch are the targets — the fully-closed-loop race is now the category’s real frontier. Drug Delivery Business + 2

Drug Delivery Business News

2. 🌐 Tandem wins expanded CE mark for type 2 and pregnancy use

Tandem’s t:slim X2 and Mobi pumps with Control-IQ+ are now CE-marked in Europe for adults with type 2 diabetes and for type 1 patients during pregnancy, backed by the 2IQP and CIRCUIT trials. Reimbursement and interoperability — not the algorithm — will decide who takes share as the closed-loop category matures. Medical Device Network

Medical Device Network

3. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.

The Commercial Launch & Impact Framework (CLIF) is a fast, external diagnostic that finds where your commercial story breaks — before a buyer or investor does. One week, an independent outside read, decision-grade clarity before you raise, launch, or scale.

See how it works →

Sponsored by RŌG Health

4. 🔬 Dexcom buys Nutrisense as level-A evidence backs CGM for type 2

At ADA, new data delivered the ADA’s highest (level A) evidence for continuous glucose monitors in type 2 non-insulin users, which Dexcom’s CEO expects to reshape the standard of care; the company also acquired metabolic-health firm Nutrisense. The CGM market is pushing decisively beyond insulin-dependent patients. MedTech Dive

MedTech Dive

5. ⚠️ BD recalls ChloraPrep and FREPP skin-prep lots over fungal contamination

BD is recalling lots of ChloraPrep Clear 1 mL and FREPP Clear 1.5 mL applicators over Aspergillus penicillioides contamination that the FDA warns can cause systemic infection, sepsis, and death if introduced during catheter placement. This is BD’s second ChloraPrep fungal recall in roughly a year — a sterility-control problem that isn’t going away. FDA

FDA

6. 🧪 Galmed pivots into GI medtech with $4.5M Colospan acquisition

Galmed signed a $4.5M definitive agreement to acquire Colospan, whose CG-100 intraluminal bypass device holds FDA Breakthrough Device status and a CE mark and is in a U.S. pivotal IDE trial; the device protects anastomotic connections after colorectal surgery and reduces the need for diverting stomas. A small deal, but a clean case study in how Breakthrough-designated devices are getting valued and acquired. Stock TitanMedical Buyer

Pharmaceutical Executive

7. 🏭 Boston Scientific to build $138M, 300-job distribution hub in Indiana

Boston Scientific will invest $138M in a 500,000-square-foot distribution and light-manufacturing facility in Plainfield, Indiana, expected to create up to 300 high-wage jobs, on top of recent investments in Ireland and Minnesota. Domestic logistics depth is becoming a competitive variable for the largest players. MassDevice

MassDevice

8. 🔧 Medline draws an FDA warning letter over cleanroom quality failures

The FDA cited 250 complaints on Medline’s angiographic syringes between June 2023 and February 2026, flagging particulate accumulation on manufacturing equipment and a last documented cleanroom-equipment cleaning dating to November 2023 — after which 114 foreign-matter complaints were logged. A textbook quality-system gap becoming a field problem. MedTech Dive

MedTech Dive

🔎 Bonus: worth a read

Founders face pressure from all sides as biotech crawls toward recovery

A dispatch from Salt Lake City’s Altitude Lab, where biotech founders — first-timers and 20-year veterans alike — talk candidly about raising capital in a risk-averse market that’s chasing AI hype over slow-moving science. A grounded look at the sequencing and storytelling challenges early-stage life science leaders are navigating right now.

BioSpace

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

A Quiet Guidance Document Just Changed What Every Device Submission Has to Answer

The medtech headlines this week belonged to the usual heavyweights — another nine-figure acquisition, another cardiovascular recall working its way through the courts. But the development most likely to touch your next submission didn't come with a press release or a stock-price move. On May 29, the FDA quietly finalized its guidance on the content of human factors information in device marketing submissions, closing out a draft that had been pending since December 2022. It is exactly the kind of document that gets skimmed and filed. It shouldn't be.

Human factors information is the evidence that a device can be used safely by its intended users — that the people operating it won’t make the kind of mistakes that injure patients. For more than a decade the FDA has folded human factors review into 510(k) and PMA evaluations, but it was never fully clear which devices actually needed validation testing in the submission itself. Two manufacturers with similar products could reasonably reach opposite conclusions. The final guidance is the agency’s attempt to end that ambiguity.

It keeps the three-tier structure from the draft. A Category 1 submission, for modified devices only, needs just a high-level summary. Category 2 needs a rationale for why the device has no critical tasks — the steps where a use error would cause harm. Category 3 requires a full human factors validation study. What’s new is a fourth checkpoint in the agency’s decision flowchart, Decision Point D, which sits after a manufacturer has already identified critical tasks and asks whether validation data actually needs to go in the submission. The answer turns on three things: the device’s history of safe use, the complexity of its user interface, and whether existing risk controls are already adequate.

On its face, Decision Point D reads like relief. Under the 2022 draft, identifying a critical task pushed you straight into a mandatory validation study. The new checkpoint creates room to argue that one isn’t necessary — that a long record of safe use for the same intended users in the same environment is justification enough. Human factors consultants have read it that way, framing the change as the agency’s growing flexibility about how use-safety gets demonstrated, with risk analysis rather than reflexive testing at the center.

The lawyers see the catch. In its analysis, Hyman, Phelps & McNamara flagged a footnote tying Decision Point D to the Quality Management System Regulation, along with a pointed recommendation that manufacturers keep human factors information on hand whether or not they submit it. The implication is that data you successfully argue out of your premarket file doesn’t disappear — it becomes something an investigator can ask for during a QMSR inspection. The work doesn’t go away. It moves from a room where you control the timing to one where the FDA does. And the firm’s experience is that review teams expect to see study results regardless, often through a request for additional information mid-review.

There’s a second change with quieter reach. The FDA updated its eSTAR templates — the structured forms nearly every submission now flows through — to require selecting a human factors category. That makes human factors a checkbox on every device application, not just the ones where it was once obviously relevant. A decision that used to be implicit is now mandatory, in writing, every time.

This is where the structural weight lands, and it doesn’t land evenly. A large manufacturer with a dedicated human factors team and a mature quality system absorbs this as a process tweak. The mid-tier innovator — a strong product, a regulatory function built for legacy 510(k) work — is the one now expected to defend a category selection, maintain inspection-ready files it may never submit, and navigate an interpretation the agency and its own consultants don’t fully agree on. That gap in readiness is itself a competitive variable.

The clock is already running. The FDA built in a roughly 60-day operationalization window and generally doesn’t expect compliant submissions before August 1, though it will review the new information sooner if offered. That leaves a narrow runway to map current pipelines against the new flowchart and decide, device by device, what to test and what to defend.

The deals and the recalls will get the clicks this week. But it’s the document nobody reads aloud that quietly rewrites what every team in the industry has to prove.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The week’s signal was risk and capital moving at once. Quality problems surfaced inside two of the industry’s biggest franchises while the consolidation engine kept running — Olympus, Boston Scientific, and DePuy Synthes all put money to work — and the FDA’s looser posture on wellness claims opened the floodgates on consumer blood-pressure features. All eyes now turn to Wednesday, when Medtronic closes out the sector’s earnings season..

8 things to watch this week:

1. 📊 Medtronic shares slide into Wednesday’s fiscal Q4 report

Medtronic fell roughly 6% in the holiday-shortened week, closing at $73.81 after four straight down sessions, ahead of fiscal Q4 and full-year results due before the open on June 3. The print caps the sector’s earnings season and follows the company’s $650M deal for SPR Therapeutics — a read on whether its growth-by-acquisition strategy is convincing investors.

TS2

2. 🫀 Boston Scientific funnels $1.5B into MiRus with an option to buy its TAVR system

Boston Scientific took a 34% stake in MiRus and secured an exclusive option to acquire its Siegel balloon-expandable TAVR platform for an additional $3 billion. The structured, optioned deal is a notable template — a route back into structural heart after exiting Acurate, without taking on full development risk up front.

Fierce Biotech

3. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Sponsored by RŌG Health

4. 💍 Blood-pressure wearables flood the market after the FDA relaxes oversight

After January guidance let companies ship sensors that “estimate, infer, or output” blood pressure for wellness purposes without authorization, Ōura debuted its Ring 5 with blood-pressure signals — and it’s far from alone. The episode marks a real line companies now have to draw between an unregulated wellness claim and a regulated medical one, and some experts are uneasy about it.

The Boston Globe / STAT

5. 🤖 Cornerstone Robotics wins CE mark for its Sentire surgical robot

The Hong Kong-based company secured EU approval for its AI-powered Sentire endoscopic platform across general surgery, gynecology, thoracic, and urology — its formal entry into Europe, following a $200M raise and early UK clinical work with Portsmouth Hospitals. Early users have noted similarities to Intuitive’s da Vinci, a sign the field’s challengers are converging on a familiar interface to ease adoption.

MassDevice

6. ⚠️ J&J’s Abiomed recalls Impella heart pumps after a patient death

J&J initiated a voluntary recall of seven Impella CP sets that don’t meet design specifications, an issue linked to one death and flagged through the company’s retrospective quality audits. It’s the latest in a long string of Impella actions, and J&J was careful to note the issue appeared in 0.01% of global cases — but the cadence keeps post-Abiomed integration risk in the spotlight.

Cardiovascular Business

7. 💉 Beta Bionics earmarks Q2 2027 for its Mint patch pump launch

Beta Bionics set a Q2 2027 commercialization target for Mint, a patch pump pairing its adaptive dosing algorithm with a 200-unit reservoir, three-day wear, and a two-piece reusable/disposable design — pending FDA clearance as an ACE pump. The tubeless category is getting more crowded just as incumbent Insulet manages quality scrutiny of its own.

Drug Delivery Business News

8. 🔓 Dexcom warns of stolen G7 sensors being resold to the public

Dexcom identified two lots of G7 sensors that were marked as scrap, sent for destruction, then stolen and sold to consumers through an unauthorized distributor. One lot carries a sterilization-related infection risk and the other an elevated failure rate — a supply-chain integrity problem that puts a spotlight on vendors’ end-of-life destruction protocols.

MobiHealthNews

🔎 Bonus: worth a read

Founders face pressure from all sides as biotech crawls toward recovery

A dispatch from Salt Lake City’s Altitude Lab, where biotech founders — first-timers and 20-year veterans alike — talk candidly about raising capital in a risk-averse market that’s chasing AI hype over slow-moving science. A grounded look at the sequencing and storytelling challenges early-stage life science leaders are navigating right now.

BioSpace

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

One FDA Approval, Four Advantages at Once: What Guardant's New Liquid Biopsy Signals for Diagnostics.

While the medtech industry’s attention this month has been on robotics launches, the IVL share fight, and a thinning FDA, a quieter milestone landed on May 20: the FDA approved a new version of Guardant Health’s Guardant360 Liquid CDx, and the stock jumped roughly 25% the same week. For a company whose core product is a blood test, a quarter of its market value moved on a label change. The market saw something structural.

Here is what the label actually says. The new assay reads a genomic footprint 100 times wider than the test it replaces — Guardant calls it the largest FDA-approved liquid biopsy panel. The seven companion diagnostic indications already cleared for the prior Guardant360 CDx carry over to the new test without re-filing. Results come back in as little as seven days. And it ships covered: Guardant says Medicare and commercial payers representing more than 300 million lives already reimburse it.

But the number that moved the stock isn’t the gene count. Guardant360 Liquid CDx is, by the company’s account, the first FDA-approved liquid biopsy to combine genomic and epigenomic profiling from a single blood draw — reading not just which mutations a tumor carries, but how its genes are switched on and off. Guardant reports a several-fold jump in sensitivity for detecting circulating tumor DNA over the prior test, and says the paired signal flags clinically actionable findings that sequencing alone would miss. Independent trade coverage of the approval described it in the same terms.

Set that against the competition. Roche’s FoundationOne Liquid CDx, the incumbent, analyzes more than 300 genes and has built its position on panel breadth and companion-diagnostic depth; Tempus won FDA clearance for its xT CDx on a similarly expansive panel. For most of the last five years, the blood-based profiling fight has been an arms race over how many genes a test could read from a tube of blood. Guardant just reframed the contest. The pitch is no longer “more genes” but “more kinds of data” — genotype plus a phenotype-adjacent layer the others don’t report. Whether epigenomic integration proves clinically decisive across tumor types is unproven, and Guardant’s broader phenotype reporting is offered as a professional service the company notes the FDA has not reviewed. What is no longer theoretical is that a regulator has now cleared an assay built on the multiomic premise.

The way Guardant got it cleared is its own lesson. The company did not file a new test from zero and argue each cancer indication over again; it brought a more capable assay through the FDA and let the prior approved claims transfer. Then it put its entire portfolio on one AI-enabled foundation it calls the Smart Platform — the same architecture now underpinning tests for early screening, recurrence monitoring, and treatment selection. One cleared core, many products hanging off it. A company that spent years and millions clearing each device as a standalone fight is looking at a different playbook.

The stakes scale with the category. The U.S. liquid biopsy market sat at roughly $2.8 billion in 2026 and is forecast to approach $8.9 billion by 2035, and it is crowded — diagnostics incumbents on one side, data-first entrants like Tempus on the other. What makes this approval stand out in that field is that it bundles four advantages a competitor would normally have to win one at a time. The first is a differentiated technical claim: the multiomic read, not just a bigger panel. The second is regulatory leverage: seven approved indications that rode forward into the new assay instead of being re-litigated. The third is reimbursement, already in place across more than 300 million covered lives before the test goes to market. The fourth is platform reach: one cleared core spreading across an entire product line. Any one of those is an edge. Assembled at once, they are a moat.

For device and diagnostics teams watching from adjacent categories, the signal travels. The basis of competition in comprehensive genomic profiling is shifting from panel size to data integration. Regulatory pathways that let approved claims ride forward into a successor assay are worth designing for from the start. And the gap between a cleared test and a commercial one increasingly comes down to whether reimbursement and platform leverage were built in before the FDA ever said yes.

SPONSORED BY RŌG HEALTH

Most medical device companies don't fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a quick, structured external diagnostic that helps you identify gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Cardiovascular set the tone over the past two weeks. J&J extended the Impella controller saga with a new correction tied to one death and two injuries. Boston Scientific posted positive pivotal data for its coronary IVL catheter and put $1.5 billion behind a TAVR upstart. Stryker disclosed it paid up to $835 million for Amplitude Vascular, sharpening competition in lithotripsy on multiple fronts at once. Around the edges: Medtronic and Olympus each added portfolio pieces, and the FDA cleared the first AI tool for continuous sepsis monitoring.

8 things to watch this week:

1. ⚠️ J&J Impella controller restart linked to one death, two injuries

The FDA issued an early alert after Johnson & Johnson’s Abiomed unit identified a software error that can force the Automated Impella Controller to restart for roughly 35 seconds mid-procedure, leaving patients unsupported. Abiomed sent customers updated use instructions on May 14 and is working on a software fix. The action extends a string of Impella controller corrections that began last summer.

MassDevice

2. 🧠 Medtronic to acquire SPR Therapeutics for $650M

Medtronic agreed to buy Cleveland-based SPR Therapeutics for roughly $650 million in cash, adding the FDA-cleared SPRINT peripheral nerve stimulation system to its neuromodulation portfolio. SPRINT delivers up to 60 days of temporary electrical stimulation through a percutaneous lead, giving Medtronic a minimally invasive option to intervene earlier in the chronic pain pathway. It’s Medtronic’s third major acquisition this year.

Fierce Biotech

3. 💗 Boston Scientific’s third swing at TAVR: $1.5B for a 34% stake in MiRus

Boston Scientific invested $1.5 billion for an approximately 34% equity stake in MiRus and an exclusive option to acquire the company’s SIEGEL balloon-expandable TAVR system through additional milestone-tied payments totaling $3 billion. The structure gives Boston Scientific a defined path back into structural heart after exiting the Acurate program last year — and a third attempt at TAVR after two prior failed efforts.

MD+DI

4. 💥 Stryker’s Amplitude Vascular deal valued at up to $835M

In a 10-Q filing, Stryker disclosed it paid approximately $435 million upfront for Amplitude Vascular Systems, with up to $400 million in milestone payments tied to regulatory and commercial targets. The investigational Pulse IVL system uses CO₂-generated pressure waves delivered through a balloon catheter to treat calcified peripheral arterial disease. The deal places Stryker squarely in an IVL market now contested by J&J/Shockwave, Abbott, and Boston Scientific.

MassDevice

5. 🧭 Most medical device companies don’t fail on technology. They fail on sequencing.

The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made in the sequencing — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.

The CLIF Analysis from RŌG Health is a fast, structured external diagnostic that surfaces those gaps before they become costly. One week. Built for medical device and medtech teams.

Learn about the CLIF →

Sponsored

6. 🔬 Boston Scientific’s SEISMIQ coronary IVL hits primary endpoints in FRACTURE

Boston Scientific reported positive pivotal results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter at EuroPCR 2026, with a 93.3% rate of freedom from major adverse cardiac events at 30 days and 93.7% procedural success across 420 patients with severely calcified coronary artery disease. The data supports a planned FDA submission and positions Boston Scientific to compete directly with J&J’s Shockwave franchise in coronary IVL.

AJMC

7. 🧬 Olympus to buy Israel’s BioProtect for $270M to expand in prostate cancer

Olympus agreed to acquire BioProtect for $270 million, picking up the company’s biodegradable balloon spacer used to separate the prostate from the rectum during radiation therapy. The device has been used in more than 11,000 procedures worldwide since its 2023 commercial launch. The deal extends Olympus’ push into oncology adjacencies after a multi-year portfolio reshaping around endoscopy and therapeutic solutions.

Medical Device Network

8. 🤖 Bayesian Health lands first-ever FDA clearance for continuous AI sepsis monitoring

The FDA granted 510(k) clearance to Bayesian Health’s TREWS platform — the first AI tool to clear the agency for continuous sepsis monitoring rather than rule-based EHR alerts. Built by Johns Hopkins researchers, the system showed 82% sensitivity for early sepsis detection in a prospective study published in Nature Medicine, and patients were 18% less likely to die in the hospital when clinicians acted on its alerts in time. Bayesian is positioning for a CMS New Technology Add-on Payment decision in early August.

24x7 Magazine

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.